Featured
A year-long investigation reveals how a small group of Silicon Valley elites sought to capture the psychedelic therapy industry — using a network of affiliated organizations to scapegoat critics while pressuring regulators to approve their botched MDMA clinical trials.
The Psychedelic Syndicate: Selected Primary Source Documents
This appendix makes available numerous previously unreleased primary source documents to serve as resources for other researchers and reporters.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
Thanks!
Now, will you support us monthly on Patreon?
Editorial
Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.
Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.
Featured
The Psychedelic Syndicate: Executive Summary
A year-long investigation reveals how a small group of Silicon Valley elites sought to capture the psychedelic therapy industry — using a network of affiliated organizations to scapegoat critics while pressuring regulators to approve their botched MDMA clinical trials.
The Psychedelic Syndicate: Part 1
October 10, 2025
Part 1 of The Psychedelic Syndicate reveals how the Psychedelic Science Funders Collaborative (PSFC) — a wealthy network of Silicon Valley elites and Burning Man devotees — systematically captured the psychedelic movement by influencing MAPS, funding its subsidiary Lykos’ MDMA clinical trials, and promoting underground therapy through state legalization initiatives.
The Psychedelic Syndicate: Part 2
October 10, 2025
Part 2 of The Psychedelic Syndicate exposes the compromised foundation of PSFC's influence network — from the abuse scandals that undermined their preferred therapy model, to undisclosed ties with the sole FDA advisory committee member who voted unequivocally for MDMA approval.
The Psychedelic Syndicate: Part 3
October 10, 2025
Part 3 of The Psychedelic Syndicate exposes how Silicon Valley's "move fast and break things" mentality infected psychedelic therapy, creating a culture where leaders rationalized patient harm as unavoidable for progress and ultimately embraced Trump administration officials who promised regulatory shortcuts.
The Psychedelic Syndicate: Part 4
October 10, 2025
Part 4 of The Psychedelic Syndicate reveals PSFC’s strategy to manufacture spiritual and moral authority through academic capture — even as some members align with far-right ideologies that deepen the very crises psychedelics are meant to heal.
The Psychedelic Syndicate: Selected Primary Source Documents
This appendix makes available numerous previously unreleased primary source documents to serve as resources for other researchers and reporters.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Hamilton’s Pharma Cope
Editorial
Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.
Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Power Tripping offers an inside look at Psymposia and New York Magazine’s podcast “Cover Story: Power Trip.” Join the co-creators and the rest of the Psymposia team for deep dives into the histories, characters, and events that shaped our investigation.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Listen on Spotify, Apple Podcasts, or wherever podcasts are available.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Featured Stories
Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.
Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.
Church of Psilomethoxin, Part 1: Sacramental Skepticism. Is the Church in Denial?
This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
#48 – Drugs and Anti-Capitalism with Hilary Agro
We talk drugs and anti-capitalism with anthropology PhD candidate, Hilary Agro. Ranging from prohibition to psychedelic clinical trials and beyond, we explore the overlaps and differences in our analyses of the current psychedelic (and broader drug policy) landscape.
#47 – Part Two: Right Wing Psychedelia
We continue our discussion about Brian Pace and Neşe Devenot's recently published paper: "Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency"
#46 – Part One: Right Wing Psychedelia
We discuss Brian Pace and Neşe Devenot's recently published paper: "Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency"
#45 – Part Two: Digital Capitalism on Psychedelics with Emma Stamm
In part two of our conversation with Villanova visiting professor of philosophy Emma Stamm, we discuss the "psychedelic industry's" increasing fixation on digital capitalism. Looking at apps like MyDelica and hardware like Kernel's brain-scanning helmet, we discuss how the social implications of this technology extend well beyond psychedelia.

Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
Series
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
A six part series on the intersection of psychedelics and capitalism, and the early investors making it happen.
From Mining to Mushrooms
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Talking Psychedelic Capitalism in a WeWork Ballroom
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.












































